CFH CC associated with more injections performed [67]
Ranibizumab
CFH and ARMS2
ARMS2 TT associated with worse visual outcomes; CFH CC associated with relatively worse visual outcomes [68]
Ranibizumab
Multiple
CFH CC associated with poor treatment response; combination heterozygotes at CFH and FZD4 associated with more favorable outcomes; no association with CFB, HTRA1, ARMS2, VEGFA, KDR, and LRP5 [69]
Ranibizumab
CFH, HTRA1, and VEGF
CFH TC associated with better visual outcomes; no association with number of injections with any gene [70]
Bevacizumab and/or ranibizumab
APOE
APOE ε4 associated with better treatment outcomes [71]